FZD10 and gastric cancer: In addition, increased plasma concentrations of Fzd10‐positive sEVs were associated with tumor progressions in colorectal and gastric cancer patients, suggesting that Fzd10 can serve as a biomarker for diagnostics and treatment response [83].